REGENXBIO RGNX 深 沪
等待开盘 11-25 09:30:00 美东时间
12.3352
+0.535
+4.54%
华盛通- 最 高12.44
- 今 开11.87
- 成交量 11.20万股
- 最 低 11.81
- 昨 收 11.80
- 总市值 6.23亿
- 52周最高 13.925
- 市盈率 静 --
- 换手率 0.22%
- 52周最低 5.035
- 委 比 73.65%
- 总股本 5051.42万
- 历史最高 85.10
- 量 比 0.68
- 振 幅 5.34%
- 历史最低 5.035
- 每 手 1
- 风险率 1.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Clearside Biomedical Inc. filed for Chapter 11 bankruptcy to maximize stakeholder value through a structured process, including auctioning its assets such as the validated SCS Microinjector platform, CLS-AX TKI program for wet AMD and diabetic retinopathy, and preclinical programs for geographic atrophy and diabetic macula edema. The company, which operates a biopharmaceutical business focused on suprachoroidal delivery of therapies to treat sigh...
11-24 12:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.
11-20 20:30
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
RBC Capital Maintains Outperform on Regenxbio, Raises Price Target to $19
RBC Capital analyst Luca Issi maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $17 to $19.
11-08 03:23
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
致敬时代丨全球近2亿人受困！针对失明的主要原因，创新疗法助他们“点亮”失去的世界
（来源：药明康德） 转自：药明康德 编者按：2025年，药明康德迎来创立25周年的重要里程碑。值此契机，我们向所有与我们共同书写产业变革篇章的科学家、医药人和投...
10-29 07:32
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced it will host a conference call on November 4, 2025, at 5:00 p.m. ET to discuss its Q3 2025 financial results and corporate updates. A live and replayed webcast will be available on the company's website for three months. The company, focused on developing therapies for rare and ultra-rare genetic diseases, employs an efficient drug development strategy to address significant unmet medical ne...
10-28 20:30
REGENXBIO to Present Data on Sura-vec for Diabetic Retinopathy at American Academy of Ophthalmology
REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will present interim data from the Phase II ALTITUDE® trial evaluating suprachoroidal delivery of surabgene lomparvovec (ABBV-RGX-314, sura-vec) for the treatment
10-09 19:25
